Legacy Private Trust
AKBA icon

Legacy Private Trust’s Akebia Therapeutics AKBA Stock Holding History

Legacy Private Trust’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.3K Hold
12,250
– – ﹤0.01% 272
2026
Q2 		$14K Hold
12,250
– – ﹤0.01% 266
2026
Q1 		$17K Hold
12,250
– – ﹤0.01% 260
2025
Q4 		$19.7K Hold
12,250
– – ﹤0.01% 258
2025
Q3 		$33.4K Hold
12,250
– – ﹤0.01% 255
2025
Q2 		$44.6K Hold
12,250
– – ﹤0.01% 248
2025
Q1 		$23.5K Hold
12,250
– – ﹤0.01% 242
2024
Q4 		$23.3K Hold
12,250
– – ﹤0.01% 236
2024
Q3 		$16.2K Hold
12,250
– – ﹤0.01% 231
2024
Q2 		$12.5K Hold
12,250
– – ﹤0.01% 227
2024
Q1 		$22.4K Buy
+12,250
New +$19.6K ﹤0.01% 227

Other funds holding AKBA

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Legacy Private Trust's AKBA Position: Q3 2026 in Review

Legacy Private Trust held its Akebia Therapeutics (AKBA) position steady in Q3 2026 at 12,250 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #272.

Legacy Private Trust first reported a position in AKBA in Q1 2024 and has held it in 11 quarters since. The position peaked at $44.6K in Q2 2025. 97 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Legacy Private Trust held 12,250 shares of Akebia Therapeutics worth $11.3K as of Q3 2026.
  • Legacy Private Trust left its Akebia Therapeutics share count unchanged in Q3 2026.
  • Akebia Therapeutics made up ﹤0.01% of Legacy Private Trust's portfolio in Q3 2026, its #272 holding.
  • Legacy Private Trust first reported a position in Akebia Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • Legacy Private Trust's Akebia Therapeutics position peaked at $44.6K in Q2 2025.
  • 97 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Legacy Private Trust's 13F filing for Q3 2026, filed 6 Oct 2026.